--- title: "Tandem Diabetes | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 247.22 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285608532.md" datetime: "2026-05-07T20:10:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285608532.md) - [en](https://longbridge.com/en/news/285608532.md) - [zh-HK](https://longbridge.com/zh-HK/news/285608532.md) --- # Tandem Diabetes | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 247.22 M Revenue: As of FY2026 Q1, the actual value is USD 247.22 M, beating the estimate of USD 240.54 M. EPS: As of FY2026 Q1, the actual value is USD -0.3, beating the estimate of USD -0.4385. #### First Quarter 2026 Financial Highlights Tandem Diabetes Care, Inc. reported record first quarter pump shipments, sales, and gross margin for the quarter ended March 31, 2026. ##### Sales - **Worldwide Sales**: Worldwide sales increased 5% to $247.2 million, compared to $234.4 million in the first quarter of 2025. In constant currency, sales increased by 2%. - **United States Sales**: United States sales increased 7% to $160.8 million, compared to $150.6 million in the first quarter of 2025. - **International Sales**: International sales increased 3% to $86.4 million, compared to $83.8 million in the first quarter of 2025. In constant currency, international sales decreased by 5%. ##### Operational Metrics - **Pump Shipments**: More than 29,000 pumps were shipped worldwide, including over 19,000 pumps in the United States and more than 10,000 pumps internationally. - **Gross Profit**: Gross profit was $136.8 million, an increase from $118.4 million in the first quarter of 2025. - **Gross Margin**: Gross margin was 55%, up 480 basis points compared to 51% in the first quarter of 2025. - **Operating Loss**: GAAP and non-GAAP operating loss was - $17.4 million, or -7% of sales, significantly improved from a GAAP operating loss of - $120.9 million (or -52% of sales) and a non-GAAP operating loss of - $109.7 million (or -47% of sales) in the first quarter of 2025. The prior year included a - $75.2 million charge for acquired in-process research and development expenses. - **Net Loss**: GAAP and non-GAAP net loss was - $20.4 million, compared to a GAAP net loss of - $130.6 million and a non-GAAP net loss of - $119.4 million in the first quarter of 2025. - **Adjusted EBITDA**: Adjusted EBITDA was $2.7 million, or 1% of sales, a substantial improvement from - $79.9 million, or -34% of sales, in the first quarter of 2025. - **Operating Expenses**: Total operating expenses were $154.2 million for Q1 2026, down from $239.3 million in Q1 2025. Selling, general and administrative expenses were $108.2 million, and research and development expenses were $46.0 million. ##### Cash Flow - **Operating Cash Flow**: Operating cash flow was $11.1 million for the first quarter of 2026, compared to - $18.3 million in the first quarter of 2025. - **Free Cash Flow**: Free cash flow was $4.8 million for the first quarter of 2026, compared to - $21.2 million in the first quarter of 2025. ##### Balance Sheet Highlights (as of March 31, 2026) - **Cash, cash equivalents and short-term investments**: Cash, cash equivalents and short-term investments totaled $570.3 million, up from $292.7 million as of December 31, 2025. - **Total Assets**: Total assets were $1,153.4 million, compared to $881.1 million as of December 31, 2025. - **Total Liabilities**: Total liabilities were $1,021.0 million, compared to $725.9 million as of December 31, 2025. - **Total Stockholders’ Equity**: Total stockholders’ equity was $132.4 million, compared to $155.2 million as of December 31, 2025. - **Convertible Senior Notes, net - long-term**: Convertible Senior Notes, net - long-term were $601.8 million, an increase from $310.0 million as of December 31, 2025. ##### Unique Operational Developments - Tandem Diabetes Care, Inc. launched a pay-as-you-go reimbursement model in the United States pharmacy channel. - The Tandem Mobi connected care ecosystem was expanded with Android compatibility. - The company demonstrated positive free cash flow and strengthened its balance sheet by completing a 0.00% convertible debt offering. #### 2026 Financial Guidance Tandem Diabetes Care, Inc. reaffirmed its financial guidance for the year ending December 31, 2026, estimating total sales between $1.065 billion and $1.085 billion. United States sales are projected between $730 million and $745 million, with international sales expected to be between $335 million and $340 million. The company anticipates a gross margin of approximately 56% to 57% of sales and an Adjusted EBITDA margin of approximately 5% to 6% of sales. ### Related Stocks - [TNDM.US](https://longbridge.com/en/quote/TNDM.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Range Impact GAAP EPS of -$0.02, revenue of $0.92M](https://longbridge.com/en/news/286725496.md) - [INTOUCH INSIGHT ANNOUNCES Q1 2026 FINANCIAL RESULTS](https://longbridge.com/en/news/287124506.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)